Vasopeptidase inhibitors simultaneously block two key enzymes — ACE and neutral endopeptidase — boosting protective natriuretic peptides while reducing harmful angiotensin, offering a dual approach to blood pressure control.
Dual mechanismOne molecule simultaneously increases protective natriuretic peptides and decreases harmful angiotensin II for superior blood pressure control
What the researchers found
Vasopeptidase inhibitors simultaneously increase natriuretic peptide levels (by blocking NEP) and decrease angiotensin II (by blocking ACE), producing superior blood pressure reduction compared to ACE inhibition alone.
Why it matters
Combining two mechanisms of blood pressure control in one molecule is more effective and simpler than taking two separate drugs. This concept influenced the development of sacubitril/valsartan (Entresto), now a standard heart failure treatment.
How the study worked
Review article covering the pharmacological rationale, preclinical data, and early clinical trial results of vasopeptidase inhibitors (dual ACE/NEP inhibitors) for cardiovascular therapy.
What this study cannot tell us
Review of early-stage clinical data. First-generation vasopeptidase inhibitors (omapatrilat) were later limited by angioedema risk. The concept was eventually refined in a different drug class.
How to read the evidence
Moderate evidence from a review of preclinical and early clinical data for a novel pharmacological concept.
When this study was published
Published in 1999. While first-generation vasopeptidase inhibitors had safety issues, this concept evolved into sacubitril/valsartan (Entresto), now a cornerstone of heart failure treatment.
The bigger picture
This concept of boosting the body's protective peptides while blocking harmful ones transformed cardiovascular drug development. It led directly to the neprilysin inhibitor concept behind sacubitril/valsartan, which has saved countless lives in heart failure.
Questions still open
- Can the angioedema risk be eliminated from dual inhibitors?
- Would vasopeptidase inhibition benefit other conditions beyond hypertension?
- Are there additional protective peptides that could be boosted through enzyme inhibition?
Common questions
What is vasopeptidase inhibition?
Are these drugs used today?
Read the original research
Vasopeptidase inhibition: a new concept in blood pressure management.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 17(1), S37-43
Citation
Burnett, J C. (1999). Vasopeptidase inhibition: a new concept in blood pressure management.. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 17(1), S37-43.